Less Ads, More Data, More Tools Register for FREE

Pin to quick picksXaar Share News (XAR)

Share Price Information for Xaar (XAR)

Share Price is delayed by 15 minutes
Get Live Data
137.00    -3.00 (-2.14%)
Bid:
137.00
Ask:
144.50
Spread: 7.50 (5.474%)
Market Cap: £107.51m
XAR Live PriceLast checked at - London Stock Exchange

Intraday Xaar Share Chart

TechMARK movers: Bumper demand for Xaar

Thu, 21st Oct 2010 13:54
Shares in print heads developer Xaar are soaring ahead following a strong trading statement and a £15m placing to finance capacity expansion. The share price has more than doubled in the past year having recovered to levels last achieved before sales problems in China. The placing is at 170p a share. Net cash was £7.8m at the end of September 2010. Xaar will spend the money expanding its Platform 3 manufacturing capacity at Huntingdon to keep up with demand for its Xaar 1001 print head. At the interim stage it had announced that the planned closure of the Scandinavian factory was not going ahead because of the strong demand for products. Demand continues to rise in the industrial and packaging markets. Margins are improving. Annual capacity will rise from 20,000 units to 45,000 units at the end of 2012. The order book is so strong that Panmure Gordon estimates that 85% of 2012 production is already covered. GlaxoSmithKline reported better than expected earnings per share before restructuring costs but it says that the operating environment is challenging. The shares fell back after the figures but they are starting to recover. Revenues were similar to expectations at £6.81bn in the three months to September 2010, against £6.76bn in the same period last year. Underlying sales growth is estimated at 6%. Pre-restructuring earnings were 28.2p a share, slightly down on the 28.5p a share reported last year. Including restructuring costs of £171m, the earnings figure is 25.3p a share. Strong cash flow enables GSK to increase its third quarter dividend by 7% to 16p a share. The ex-dividend date is 27 October. Net debt fell by £652m to £8.8bn at the end of September 2010. FTSE TechMARK - RisersXaar (XAR) 212.50p +19.38%Cryptologic Ltd. (CRP) 65.00p +18.18%Vectura Group (VEC) 60.75p +10.45%NXT (NTX) 4.13p +10.13%Asterand (ATD) 11.50p +9.52%Gresham Computing (GHT) 22.00p +7.32%Renovo Group (RNVO) 31.00p +6.90%BT Group (BT.A) 155.50p +3.53%Oxford Biomedica (OXB) 10.50p +2.44%Sepura (SEPU) 45.00p +2.27%FTSE TechMARK - FallersNetwork Technology (NTY) 600.00p -7.69%Filtronic (FTC) 34.50p -5.48%Psion (PON) 89.00p -5.32%Anite (AIE) 53.50p -2.73%ProStrakan Group (PSK) 74.00p -2.63%KCOM Group (KCOM) 50.75p -2.40%E2V Technologies (E2V) 94.75p -2.32%Dialight (DIA) 440.00p -2.22%GlaxoSmithKline (GSK) 1,265.50p -2.05%Innovation Group (TIG) 13.50p -1.82%

Related News

GSK says US FDA approves urinary tract infection treatment Utebzi
2 hours ago

GSK says US FDA approves urinary tract infection treatment Utebzi

(Alliance News) - GSK PLC and Spero Therapeutics Inc on Wednesday said that the US Food & Drug Administration has approved Utebzi, an oral antibiotic ...

GSK drug momelotinib gains regulatory nods as VEXAS treatment
5 days ago

GSK drug momelotinib gains regulatory nods as VEXAS treatment

(Alliance News) - GSK PLC on Friday announced that momelotinib has received orphan drug designation from the US Food & Drug Administration, and the Eu...

GSK's momelotinib receives orphan drug designation from US and EU watchdogs
5 days ago

GSK's momelotinib receives orphan drug designation from US and EU watchdogs

(Sharecast News) - Drugmaker GSK said on Friday that its JAK inhibitor momelotinib has been granted orphan drug designation by both the US Food and Dr...

Xaar News

EARNINGS: Regional REIT ups dividend but warns of "subdued" market
24 Mar 2026

EARNINGS: Regional REIT ups dividend but warns of "subdued" market

(Alliance News) - The following is a round-up of earnings for London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Xaar reports return to profitability
24 Mar 2026

Xaar reports return to profitability

(Sharecast News) - Xaar reported a return to profitability on an adjusted basis for 2025 on Tuesday, as revenue growth in its core printhead business ...

TRADING UPDATES: DP Poland sales rise, M Winkworth cuts forecast
14 Jan 2026

TRADING UPDATES: DP Poland sales rise, M Winkworth cuts forecast

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

LONDON BROKER RATINGS: Berenberg cuts Xaar price target but stays buy
31 Dec 2025

LONDON BROKER RATINGS: Berenberg cuts Xaar price target but stays buy

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning:

LONDON BRIEFING: Harbour Energy made operator of Zama in Mexico
31 Dec 2025

LONDON BRIEFING: Harbour Energy made operator of Zama in Mexico

(Alliance News) - Harbour Energy says it has been made operator of an asset in Mexico, while Digital 9 says the bulk of the proceeds from the sale of ...

SMALL-CAP WINNERS: Vp trading in line with full-year consensus
10 Oct 2025

SMALL-CAP WINNERS: Vp trading in line with full-year consensus

(Alliance News) - The following stocks are the leading risers and fallers among London Main Market small-caps on Tuesday.